Novartis: Korea green-lights Novartis' Cosentyx for kids with severe psoriasis
Novartis has scored a win in Korea's reimbursement system, clearing its immunosuppressant Cosentyx (secukinumab) for use in children and teens with chronic, severe plaque psoriasis, an age group long barred from advanced treatment options.Starting Tuesday, patients aged six to 18 with symptoms persi
Read full article »
Novartis is a Switzerland-based multinational medicines company that researches and develops generic and pharmaceutical products for the healthcare industry.
Read more